Trial Profile

A phase II trial of CS2009 in combination therapies for advanced solid tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CS 2009 (Primary)
Indications Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Therapeutic Use

17 Feb 2026 According to a CStone Pharmaceuticals media release, The Phase II study is currently actively enrolling patients in Australia.
17 Feb 2026 According to a CStone Pharmaceuticals media release, company announced that the Investigational New Drug (IND) application for the Phase II clinical trials of CS2009 combination therapies for advanced solid tumors has been approved by the China National Medical Products Administration (NMPA).
26 Sep 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com